shengnuo biotechnology: Fertility drug “Atosiban Acetate Injection” passed the consistency evaluation of generic drugs

shengnuo biotechnologylogical (688117.SH) announced that Chengdu shengnuo biotechnology-Pharmaceutical Co., Ltd.

(“shengnuo biotechnologypharmaceutical”), a wholly-owned subsidiary of the company, has recently received the approval issued by the State Drug Administration (“NMPA”) regarding the The “Approval Notice of Drug Supplementary Application” for Atosiban Acetate Injection, which has passed the quality and efficacy consistency evaluation of generic drugs.

It is reported that the company’s atosiban acetate preparation is mainly used as a drug for the treatment of premature fetuses, which can inhibit uterine contractions, reduce the secretion of prostaglandins mediated by the cyclic peptide oxytocin, and achieve the purpose of protecting the fetus.